(Q37412294)

English

Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.

scientific article published on 21 September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. (English)

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

rhabdomyosarcoma

1 reference

based on heuristic

inferred from title

Moody D. Wharam

9

object named as

Moody D Wharam

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

William H. Meyer

13

object named as

William H Meyer

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

James R. Anderson

12

object named as

James R Anderson

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Douglas S Hawkins

3

object named as

Douglas S Hawkins

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

author name string

Carola A S Arndt

1

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Julie A Stoner

2

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

David A Rodeberg

4

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Andrea A Hayes-Jordan

5

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Charles N Paidas

6

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

David M Parham

7

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Lisa A Teot

8

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

John C Breneman

10

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Sarah S Donaldson

11

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

language of work or name

0 references

publication date

21 September 2009

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

27

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

31

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

5182-5188

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from th

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773476

6 September 2017

Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773476

6 September 2017

Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773476

6 September 2017

Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773476

6 September 2017

The Intergroup Rhabdomyosarcoma Study-II.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773476

6 September 2017

Biology and therapy of pediatric rhabdomyosarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773476

6 September 2017

The Intergroup Rhabdomyosarcoma Study-I. A final report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773476

6 September 2017

Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773476

6 September 2017

Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncolog

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773476

26 June 2018

Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhi

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773476

26 June 2018

Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773476

26 June 2018

Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773476

2 September 2018

Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: a Children's Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773476

2 September 2018

Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773476

2 September 2018

Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2773476

2 September 2018

Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children

1 reference

https://pubmed.ncbi.nlm.nih.gov/19770373

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19770373

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide dose intensification during induction therapy for intermediate-risk pediatric rhabdomyosarcoma is feasible but does not improve outcome: a report from the soft tissue sarcoma committee of the children's oncology group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19770373

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Third Intergroup Rhabdomyosarcoma Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19770373

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: the Children's Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19770373

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma Study IV

1 reference

https://pubmed.ncbi.nlm.nih.gov/19770373

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.22.3768

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37412294&oldid=2177972328"